Limagne et.al suggested that TIM-3 blockade could restore in vitro the CD8 secreting property in PBMCs from lung cancer patients when used in combination with the anti-PD-1 antibody, suggesting that anti-TIM-3 reverses resistance to anti-PD-1 [55]. This evidence concerns the gene HAVCR2 and lung cancer.